Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
GlaxoSmithKline Positioning For Clinical Trial Data AdvantageAlan Kotok • Mon, Nov 26, 2012
-
Glaxosmithkline plc Q4 2009 Earnings Call TranscriptThu, Feb 4, 2010
-
Human Genome Sciences Inc. Q1 2009 Earnings Call TranscriptWed, Apr 29, 2009 • 1 Comment
-
Human Genome Sciences Inc Q4 2008 Earnings Call TranscriptThu, Feb 26, 2009
-
Human Genome Sciences Inc. Q3 2008 Earnings Call TranscriptThu, Nov 6, 2008
-
Human Genome Sciences Inc. Q2 2008 Earnings Call TranscriptWed, Jul 30, 2008
-
Human Genome Sciences Inc. Q1 2008 Earnings Call TranscriptMon, May 5, 2008
-
at MarketWatch.com (Mon, 12:34PM)
-
at CNBC.com (Sun, 10:05AM)
-
at MarketWatch.com (Fri, 6:30AM)
-
at CNBC.com (Jun 11, 2013)
-
at CNBC.com (Jun 3, 2013)
-
Business Wire (Jun 3, 2013)
-
at CNBC.com (May 30, 2013)
-
at MarketWatch.com (May 29, 2013)
-
at MarketWatch.com (May 29, 2013)
-
at MarketWatch.com (May 28, 2013)
-
at MarketWatch.com (May 28, 2013)
-
at MarketWatch.com (May 13, 2013)
-
at MarketWatch.com (May 13, 2013)
-
PR Newswire (May 10, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 19, 2013)
GSK vs. ETF Alternatives
Company Description
Human Genome Sciences, Inc. (“HGS” or the “Company”) is a commercially focused biopharmaceutical company advancing toward the market with three products in late-stage development: BENLYSTAtm for systemic lupus erythematosus (“SLE”), ZALBINtm for chronic hepatitis C, and raxibacumab for... More



















